Additional transparency disclosures

Since March 2018, Intercept has partnered with AOP Orphan Pharmaceuticals AG (HQ Vienna, Austria) in a number of European countries where Intercept does not have a direct affiliate presence. Although Intercept retains the Marketing Authorisation across Europe, AOP takes full commercialisation responsibility of OCALIVA in these countries.

Intercept is committed to ensuring transparency around interactions with Healthcare Professionals, Healthcare Organizations and Patient Organizations in line with legal and code obligations. The below links provide transparency disclosure information in these countries as they relate to Intercept:

• Finland
• Sweden
• Belgium
• Netherlands